[go: up one dir, main page]

AR027391A1 - Composiciones farmaceuticas de toxina botulinica - Google Patents

Composiciones farmaceuticas de toxina botulinica

Info

Publication number
AR027391A1
AR027391A1 ARP010100574A ARP010100574A AR027391A1 AR 027391 A1 AR027391 A1 AR 027391A1 AR P010100574 A ARP010100574 A AR P010100574A AR P010100574 A ARP010100574 A AR P010100574A AR 027391 A1 AR027391 A1 AR 027391A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical compositions
toxin pharmaceutical
botulin toxin
polysaccharide
amino acid
Prior art date
Application number
ARP010100574A
Other languages
English (en)
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23988236&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR027391(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AR027391A1 publication Critical patent/AR027391A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Una composicion farmacéutica de toxina botulínica libre de albumina derivada de la sangre, que comprende una toxina botulínica, cloruro de sodio o agua yun polisacárido tal como un hidroxietil almidon y/o un aminoácido, siendo la composicion farmacéu tica adecuada para la administracion terapéutica a unpaciente humano. Alternativamente, el polisacárido y el aminoácido pueden ser reemplazados por la albumina recombinante.
ARP010100574A 2000-02-08 2001-02-08 Composiciones farmaceuticas de toxina botulinica AR027391A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50014700A 2000-02-08 2000-02-08

Publications (1)

Publication Number Publication Date
AR027391A1 true AR027391A1 (es) 2003-03-26

Family

ID=23988236

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010100574A AR027391A1 (es) 2000-02-08 2001-02-08 Composiciones farmaceuticas de toxina botulinica

Country Status (19)

Country Link
US (2) US20020064536A1 (es)
EP (4) EP1398038B2 (es)
JP (7) JP2003522154A (es)
KR (3) KR100753765B1 (es)
CN (2) CN1258379C (es)
AR (1) AR027391A1 (es)
AT (2) ATE519494T1 (es)
AU (2) AU2001233315B2 (es)
BR (1) BR0108173A (es)
CA (3) CA2400318C (es)
CY (1) CY1108007T1 (es)
DE (2) DE60125986T3 (es)
DK (3) DK1253932T3 (es)
ES (3) ES2237551T3 (es)
MX (1) MXPA02007519A (es)
NZ (2) NZ520201A (es)
PT (3) PT1253932E (es)
TW (2) TWI317283B (es)
WO (1) WO2001058472A2 (es)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
PT1253932E (pt) * 2000-02-08 2005-07-29 Allergan Inc Composicoes farmaceuticas de toxina botulinica
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
DE10035156A1 (de) * 2000-07-19 2002-02-07 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Proteinkomplex als Vehikel für oral verfügbare Protein-Arzneimittel
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
US7140371B2 (en) * 2002-03-14 2006-11-28 Allergan, Inc. Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins
WO2003082315A1 (fr) * 2002-03-29 2003-10-09 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Remede contre l'hypermyotonie
US7491403B2 (en) * 2002-12-20 2009-02-17 Botulinum Toxin Research Associates Pharmaceutical botulinum toxin compositions
US7459164B2 (en) 2002-05-28 2008-12-02 Botulinum Toxin Research Associates, Inc. Composition for therapeutic and cosmetic botulinum toxin
US7691394B2 (en) 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
US7238357B2 (en) 2002-11-05 2007-07-03 Allergan, Inc. Methods for treating ulcers and gastroesophageal reflux disease
WO2004089335A2 (en) * 2003-03-31 2004-10-21 Alza Corporation Non-aqueous single phase vehicles and formulations utilizing such vehicles
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
FR2855177B1 (fr) * 2003-05-23 2005-07-08 Raymond Robert Composition contenant des acides nucleiques lyophilises en presence de collagene et de disaccharides
US7148041B2 (en) * 2003-09-25 2006-12-12 Allergan, Inc. Animal product free media and processes for obtaining a botulinum toxin
US7160699B2 (en) 2003-09-25 2007-01-09 Allergan, Inc. Media for clostridium bacterium and processes for obtaining a clostridial toxin
US7452697B2 (en) 2003-09-25 2008-11-18 Allergan, Inc. Chromatographic method and system for purifying a botulinum toxin
US20050191321A1 (en) 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US20100266638A1 (en) 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US9078892B2 (en) * 2004-02-26 2015-07-14 Allergan, Inc. Methods for treating pain and for treating a medication overuse disorder
US7691381B2 (en) 2004-04-15 2010-04-06 Allergan, Inc. Stabilized biodegradable neurotoxin implants
RU2255761C1 (ru) * 2004-07-01 2005-07-10 Общество с ограниченной ответственностью "Токсины и сопутствующие продукты" Препарат для лечения мышечных дистоний из токсина культуры clostridium botulinum и способ его получения
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
ES2479515T3 (es) 2004-07-26 2014-07-24 Merz Pharma Gmbh & Co. Kgaa Composición terapéutica con una neurotoxina botulínica
PT2813239T (pt) 2004-08-04 2017-06-09 Ipsen Biopharm Ltd Composição farmacêutica contendo a neurotoxina botulínica a2
EP1778279B1 (en) * 2004-08-04 2014-12-03 Ipsen Biopharm Limited Pharmaceutical composition containing botulinum neurotoxin a2
WO2006073410A1 (en) * 2005-01-03 2006-07-13 Botulinum Toxin Research Associates, Inc. Compositions, methods and devices for preparing less painful botulinum toxin formulations
US7727537B2 (en) 2005-02-14 2010-06-01 Dpm Therapeutics Corp. Stabilized compositions for topical administration and methods of making same
US7838011B2 (en) 2005-02-14 2010-11-23 Pankaj Modi Stabilized protein compositions for topical administration and methods of making same
BRPI0508299A (pt) * 2005-03-03 2007-07-31 Allergan Inc sistema livre de produto animal e processo para purificação de uma toxina botulina
KR20070110402A (ko) * 2005-03-03 2007-11-16 레반스 테라퓨틱스 보툴리눔 독소의 국소 적용 및 경피 전달을 위한 조성물 및방법
US8926991B2 (en) * 2005-06-14 2015-01-06 Botulinum Toxin Research Associates, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
US20230390368A1 (en) * 2005-06-27 2023-12-07 Revance Therapeutics, Inc. Methods of Treating Cervical Dystonia in a Subject Having Underlying Condition(s)
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
FR2889936B1 (fr) 2005-09-01 2007-12-21 Sod Conseils Rech Applic Methode pour quantifier une neurotoxine cholinergique dans un echantillon
US7744904B1 (en) * 2005-09-26 2010-06-29 B.B. Scientific L.L.C. Stabilization of Clostridium botulinum neurotoxin complex
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
AU2013202329B2 (en) * 2005-10-06 2016-04-14 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
US8137677B2 (en) 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
WO2007044809A2 (en) * 2005-10-11 2007-04-19 Botulinum Toxin Research Associates, Inc. Albumin-free botulinum toxin based pharmaceutical compositions containing a hyaluronidase and methods of use
CN100384993C (zh) * 2005-11-02 2008-04-30 浙江大学 提高地衣芽孢杆菌zjuel31410弹性蛋白酶稳定性的方法
FR2896693B1 (fr) * 2006-01-27 2008-03-14 Sod Conseils Rech Applic Composition comprenant plusieurs toxines botuliques
DE102006019447A1 (de) * 2006-04-24 2007-10-25 Dressler, Dirk, Dr. Markierung von Botulinum Toxin
EP2029740B1 (en) 2006-05-31 2012-06-20 Genzyme Corporation Use of polysaccharides for promotion of enzymatic activity
FR2902341B1 (fr) 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
FR2907680B1 (fr) 2006-10-27 2012-12-28 Scras Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux
FR2910327B1 (fr) 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
CN102988995A (zh) * 2006-12-29 2013-03-27 雷文斯治疗公司 用源自hiv-tat的多肽片段稳定的肉毒杆菌毒素的组合物及其局部施用和透皮递送的方法
GB0705245D0 (en) 2007-03-19 2007-04-25 Stabilitech Ltd Stable biological products
EP2167117B1 (en) * 2007-06-13 2012-08-15 CSL Behring GmbH Use of vwf stabilized fviii preparations for extravascular administration in the therapy and prophylactic treatment of bleeding disorders
CA2690773C (en) 2007-07-10 2013-09-17 Medy-Tox, Inc. Pharmaceutical liquid composition of botulinum toxin with improved stability
US7473429B1 (en) * 2007-07-27 2009-01-06 Renfroe J Ben Method for treatment of laminitis in animals
JP2009132686A (ja) * 2007-10-26 2009-06-18 Okayama Univ ボツリヌス毒素由来のポリペプチド及びボツリヌス毒素の検出方法
EP2072057A1 (en) 2007-12-21 2009-06-24 Merz Pharma GmbH & Co.KGaA Early administration of Botulinum toxin in the treatment of cerebrovascular event and spinal cord injury
EP2072039A1 (en) 2007-12-21 2009-06-24 Merz Pharma GmbH & Co.KGaA Use of a neurotoxic component of Clostridium botulinum toxin complex to reduce or prevent side effects
US9107815B2 (en) 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
FR2930447B1 (fr) 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
US20100034853A1 (en) * 2008-08-05 2010-02-11 Solstice Neurosciences, Inc. Compositions of activated botulinum toxin type B
US20100034854A1 (en) * 2008-08-05 2010-02-11 Solstice Neurosciences, Inc. Compositions of activated botulinum holotoxin type B (150 KD)
WO2010051039A1 (en) * 2008-11-03 2010-05-06 Solstice Neurosciences, Inc. Compositions of activated botulinum toxin type b
US20100112006A1 (en) * 2008-11-03 2010-05-06 Solstice Neurosciences, Inc. Compositions of activated botulinum holotoxin type B (150 kD)
EP2364168A1 (en) 2008-12-04 2011-09-14 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
EP3067049A1 (en) * 2008-12-10 2016-09-14 Allergan, Inc. Clostridial toxin pharmaceutical compositions
EP3332805B1 (en) 2008-12-31 2022-02-23 ReVance Therapeutics, Inc. Injectable botulinum toxin formulations
US20100184685A1 (en) * 2009-01-19 2010-07-22 Zavala Jr Gerardo Systems and methods for treating post- operative, acute, and chronic pain using an intra-muscular catheter administrated combination of a local anesthetic and a neurotoxin protein
EP2248518B1 (en) 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
AU2010265888A1 (en) 2009-06-25 2012-01-19 Revance Therapeutics, Inc. Albumin-free botulinum toxin formulations
US8129139B2 (en) 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
WO2011112996A2 (en) * 2010-03-12 2011-09-15 Surmodics, Inc. Injectable drug delivery system
JP5769379B2 (ja) * 2010-03-17 2015-08-26 グンゼ株式会社 Ｄａｎｃｅタンパク質溶液
JP2013545504A (ja) * 2010-10-06 2013-12-26 アラーガン、インコーポレイテッド ボツリヌス毒素の貯蔵およびその後の取り扱いのためのシステム
WO2012048854A2 (en) 2010-10-12 2012-04-19 Merz Pharma Gmbh & Co. Kgaa Formulation suitable for stabilizing proteins, which is free of mammalian excipients
EP2692350B2 (en) * 2011-03-31 2023-06-28 Medy-Tox Inc. Lyophilized preparation of botulinum toxin
KR101135486B1 (ko) * 2011-05-25 2012-04-13 함종욱 보툴리눔 에이형 독소의 액상제품
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
CN104189891B (zh) * 2014-08-15 2016-03-30 北京四环生物制药有限公司 一种不含人血清蛋白的重组人促红素制剂
MX2017007476A (es) 2014-12-23 2018-01-25 Merz Pharma Gmbh & Co Kgaa Recipiente precargado con toxina botulinica.
RU2722290C2 (ru) 2015-02-03 2020-05-28 Мерц Фарма Гмбх Унд Ко. Кгаа Контейнер, предварительно заполненный ботулиновым токсином
AU2016343748A1 (en) 2015-10-29 2018-05-17 Revance Therapeutics, Inc. Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect
WO2017188618A1 (en) * 2016-04-26 2017-11-02 Korea Prime Pharm Co., Ltd. A novel composition comprising botulinum toxin
WO2017203038A1 (en) * 2016-05-27 2017-11-30 Ipsen Biopharm Limited Liquid neurotoxin formulation stabilized with tryptophan or tyrosine
WO2018038301A1 (en) 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
WO2018038585A1 (ko) * 2016-08-26 2018-03-01 주식회사 에이비바이오 보툴리눔 독소 및 안정화제를 포함하는 액상 제형 및 이의 제조방법
ES2755816T5 (es) 2016-09-13 2022-10-24 Allergan Inc Composiciones de toxinas de Clostridium no proteicas estabilizadas
WO2019046311A1 (en) 2017-08-28 2019-03-07 Revance Therapeutics, Inc. TRANSMUCOSAL COMPOSITIONS OF BOTULINUM TOXIN, KITS AND METHODS FOR TREATING BLADDER DISORDERS
KR20190038292A (ko) * 2017-09-29 2019-04-08 한국프라임제약주식회사 효능 지속시간이 연장된 보툴리눔 독소 조성물
CA3082264C (en) * 2017-11-17 2024-04-16 Swedish Orphan Biovitrum Ab (Publ) Syringe assembly with ion-exchange material
KR102063475B1 (ko) * 2018-02-22 2020-01-09 주식회사 에이비바이오 보툴리눔 독소, 안정화제, 및 국소마취제를 포함하는 액상 제형 및 이의 제조방법
KR102259423B1 (ko) * 2018-11-30 2021-06-02 주식회사 휴온스바이오파마 보툴리눔 독소의 안정화 액상 조성물
WO2020111852A1 (ko) 2018-11-30 2020-06-04 주식회사 휴온스글로벌 보툴리눔 독소의 안정화 액상 조성물
JP2023515918A (ja) 2020-01-13 2023-04-17 デュレクト コーポレーション 不純物が低減された徐放性薬物送達システム及び関連の方法
US20230165946A1 (en) * 2020-04-08 2023-06-01 Medytox Inc. Botulinum toxin pre-filled injectable formulation that facilitates discharge rate control and is stable
KR102404217B1 (ko) * 2020-04-08 2022-06-02 (주)메디톡스 토출 속도 조절이 용이하고 안정한 보툴리눔 독소 사전충전된 주사기 제형
CN111675754A (zh) * 2020-05-19 2020-09-18 四川一埃科技有限公司 一种肉毒毒素蛋白晶体结构及晶体制备方法和解析方法
KR20250003215A (ko) 2023-06-30 2025-01-07 주식회사 휴온스바이오파마 폴리솔베이트 20 및 세린을 포함하는 보툴리눔 독소의 안정화 액상 조성물

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5625041A (en) * 1990-09-12 1997-04-29 Delta Biotechnology Limited Purification of proteins
US3269912A (en) * 1963-04-08 1966-08-30 Boehringer & Soehne Gmbh Aluminum oxide depot vaccines
US3758382A (en) * 1968-07-26 1973-09-11 Us Navy Ve agent process of freezing blood using a hydroxyalkyl starch as cryoprotecti
GB1514720A (en) * 1974-10-07 1978-06-21 Secr Defence Preparation of hydroxyethyl starch
DE2457047C3 (de) * 1974-12-03 1979-10-31 Behringwerke Ag, 3550 Marburg Verfahren zur Herstellung eines Derivates der leichten Kette des Tetanustoxins, dessen Verwendung zur Tetanusprophylaxe
NZ199722A (en) * 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4391801A (en) * 1981-10-29 1983-07-05 Cutter Laboratories, Inc. Plasma protein fraction substantially free of acetate ions
US4457916A (en) * 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
JPS5959625A (ja) * 1982-09-28 1984-04-05 Dainippon Pharmaceut Co Ltd ガン壊死因子を安定化する方法
HU188847B (en) * 1983-02-22 1986-05-28 Human Oltoanyagtermeloe Es Kutato Intezet,Hu Process for producing liophylized combined vaccines
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
JPS61161222A (ja) * 1985-01-09 1986-07-21 Takeda Chem Ind Ltd γ型インタ−フエロンフラグメントの組成物
EP0150067A3 (en) * 1984-01-23 1986-12-30 Takeda Chemical Industries, Ltd. Stable composition of gamma-interferon
JPS60258125A (ja) * 1984-06-06 1985-12-20 Hayashibara Biochem Lab Inc 蛋白性生理活性物質を含有する水溶性乾燥物
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
JPS61194034A (ja) * 1985-02-25 1986-08-28 Teijin Ltd 経鼻投与用粉末状組成物
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
DE3621828A1 (de) * 1986-06-28 1988-01-14 Biotest Pharma Gmbh Stabilisierung eines fuer therapeutische zwecke, insbesondere beim menschen, bestimmten interleukin-2-praeparates sowie dieses praeparat enthaltende stabilisierte waessrige loesung oder feststoff
JPH0696536B2 (ja) * 1988-02-26 1994-11-30 佐藤製薬株式会社 制酸剤含有内用懸濁液
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
FR2630115B1 (fr) * 1988-04-14 1994-10-28 Merieux Inst Procede de stabilisation des solutions d'albumine humaine et solution obtenue
FR2649991B2 (fr) † 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5919665A (en) * 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
US5945098A (en) * 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
AU7489091A (en) * 1990-03-01 1991-09-18 Agouron Pharmaceuticals, Inc. Enhanced cryopreservation with thermal hysteresis peptide
US5401243A (en) * 1990-08-21 1995-03-28 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
KR920004485A (ko) * 1990-08-30 1992-03-27 다니엘 에이. 스콜라 친수성 중합체 및 이와 상이한 친수성 물질로 이루어진 신규 조성물
US5695956A (en) * 1990-11-26 1997-12-09 University Of Pittsburgh Of The Commonwealth System Of Higher Education Clostridium perfingens type a enterotoxin toxoid and methods of preparation and use as a vaccine and therapeutic agent
JP2916947B2 (ja) * 1990-11-28 1999-07-05 興和株式会社 Ｃｐｂ―ｉの安定化方法及び製剤組成物
US5704297A (en) * 1991-02-06 1998-01-06 The Dupont Merck Pharmaceutical Company Dry powder composition of hydroxyethyl starch suitable for reconstitution
ES2109362T3 (es) * 1991-06-21 1998-01-16 Univ Cincinnati Unas proteinas administrables oralmente y metodo para hacerlas.
AU2309692A (en) * 1991-07-03 1993-02-11 Cryolife, Inc. Method for stabilization of biomaterials
JPH0672891A (ja) * 1992-08-31 1994-03-15 Green Cross Corp:The ヒト血清アルブミン含有製剤
EP0654040A1 (en) * 1992-06-23 1995-05-24 Interactive Biologics Associates Pharmaceutical composition containing botulinum b complex
US5445817A (en) * 1992-08-21 1995-08-29 The United States Of America As Represented By The Department Of Health And Human Services Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines
US5728553A (en) * 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
EP0593176A3 (en) * 1992-09-28 1995-03-01 Wisconsin Alumni Res Found Pharmaceutical compositions containing botulinum toxin and method of manufacture.
US5466672A (en) * 1992-12-04 1995-11-14 Ophidian Pharmaceuticals, Inc. Therapeutic use of clostridium difficile toxin A
JP3007785B2 (ja) * 1993-03-16 2000-02-07 旭化成工業株式会社 トロンボモジュリン組成物およびその変性防止方法
US5562907A (en) * 1993-05-14 1996-10-08 Arnon; Stephen S. Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
DK0701455T3 (da) * 1993-06-04 2001-06-18 Biotime Inc Plasmalignende opløsning
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
JP3533687B2 (ja) * 1993-12-17 2004-05-31 三菱ウェルファーマ株式会社 ヒト血清アルブミンの脱色方法
JP3684584B2 (ja) * 1993-12-17 2005-08-17 三菱ウェルファーマ株式会社 ヒト血清アルブミンの脱色方法
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
AU2431995A (en) * 1994-05-09 1995-11-29 William J. Binder Method for reduction of headache pain
US5670484A (en) * 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
JPH07308199A (ja) † 1994-05-18 1995-11-28 Green Cross Corp:The ヒト血清アルブミンの製造方法
EP0773781B1 (en) * 1994-08-04 2003-10-22 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
WO1996005222A1 (en) * 1994-08-08 1996-02-22 Wisconsin Alumni Research Foundation Purification and pharmaceutical compositions containing type g botulinum neurotoxin
US5756468A (en) * 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
US5512547A (en) * 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
AU6034396A (en) * 1995-06-06 1996-12-24 L. Bruce Pearce Improved compositions and methods for chemodenervation using neurotoxins
US5919463A (en) * 1995-07-07 1999-07-06 Oravax, Inc. Clostridium difficle toxins as mucosal adjuvants
JP3098401B2 (ja) * 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤
DE19538687A1 (de) * 1995-10-17 1997-04-24 Boehringer Mannheim Gmbh Stabile pharmazeutische Darreichungsformen enthaltend Parathormon
US5837265A (en) * 1996-03-08 1998-11-17 The Regents Of The University Of California Chemically-modified clostridiatoxin with improved properties
ES2200153T3 (es) * 1996-03-13 2004-03-01 Delta Biotechnology Limited Control de fermentacion.
US5721215A (en) * 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
US5908825A (en) * 1997-01-09 1999-06-01 University Of Maryland At Baltimore Dosage composition for nasal delivery and method of use of the same
JPH10245400A (ja) * 1997-02-28 1998-09-14 Eiken Chem Co Ltd トランスフェリンレセプターの安定化方法
JPH10251161A (ja) * 1997-03-11 1998-09-22 Green Cross Corp:The 浮腫治療効果増強剤
US6210683B1 (en) * 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
US6051239A (en) * 1997-10-20 2000-04-18 Thomas Jefferson University Compositions and methods for systemic delivery of oral vaccines and therapeutic agents
ES2179414T3 (es) * 1997-11-22 2003-01-16 Roche Diagnostics Gmbh Procedimiento mejorado de estabilizacion de proteinas.
US6346519B1 (en) * 1998-09-09 2002-02-12 Advanced Medical Instruments Method and composition for treating arthritis
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US6358917B1 (en) * 1999-08-24 2002-03-19 Jean D. A. Carruthers Cosmetic use of botulinum toxin for treatment of downturned mouth
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6139845A (en) * 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US6337075B1 (en) * 2000-01-11 2002-01-08 Allergan Sales, Inc. Methods for treating diabetes
PT1253932E (pt) * 2000-02-08 2005-07-29 Allergan Inc Composicoes farmaceuticas de toxina botulinica
JP2003009897A (ja) * 2001-07-03 2003-01-14 Keiji Oguma ボツリヌス毒素の分離・精製法
MXPA01011542A (es) * 2001-11-13 2003-05-22 Alcon Inc Regeneracion del cartilago articular da°ado por la osteoartritis de grado i y ii, mediante la aplicacion intra-articular de una mezcla de hialuronato de sodio y de condroitin sulfato en un vehiculo de gel.

Also Published As

Publication number Publication date
KR20060090938A (ko) 2006-08-17
CA2400318A1 (en) 2001-08-16
ES2275992T5 (es) 2011-05-18
WO2001058472A3 (en) 2002-01-03
KR100799400B1 (ko) 2008-01-30
JP2007332155A (ja) 2007-12-27
EP1514556A1 (en) 2005-03-16
CN1331532C (zh) 2007-08-15
JP5080902B2 (ja) 2012-11-21
KR100665469B1 (ko) 2007-01-04
MXPA02007519A (es) 2004-10-15
JP2003522154A (ja) 2003-07-22
JP2012031194A (ja) 2012-02-16
KR100753765B1 (ko) 2007-08-31
WO2001058472A2 (en) 2001-08-16
CA2494241C (en) 2011-06-14
JP2005179375A (ja) 2005-07-07
EP1253932B1 (en) 2005-04-27
AU3331501A (en) 2001-08-20
DK1253932T3 (da) 2005-06-27
EP1398038A1 (en) 2004-03-17
JP4118830B2 (ja) 2008-07-16
EP1253932A2 (en) 2002-11-06
EP1586329A1 (en) 2005-10-19
DE60125986T3 (de) 2011-07-28
CY1108007T1 (el) 2013-09-04
ATE293988T1 (de) 2005-05-15
ES2275992T3 (es) 2007-06-16
DE60110372D1 (de) 2005-06-02
DE60110372T2 (de) 2006-01-19
AU2001233315B2 (en) 2004-07-08
ES2368061T3 (es) 2011-11-14
DK1398038T3 (da) 2007-04-02
DE60125986T2 (de) 2007-10-18
CN1398188A (zh) 2003-02-19
BR0108173A (pt) 2003-01-21
EP1514556B1 (en) 2011-08-10
DK1398038T4 (da) 2011-03-28
DK1514556T3 (da) 2011-10-24
JP2011251988A (ja) 2011-12-15
PT1514556E (pt) 2011-09-08
DE60125986D1 (de) 2007-02-22
CN1258379C (zh) 2006-06-07
TW200711657A (en) 2007-04-01
EP1398038B2 (en) 2011-01-26
CA2478621C (en) 2006-11-21
KR20060028475A (ko) 2006-03-29
CN1616084A (zh) 2005-05-18
JP2004256545A (ja) 2004-09-16
US20020064536A1 (en) 2002-05-30
ATE519494T1 (de) 2011-08-15
ES2237551T3 (es) 2005-08-01
JP2005336201A (ja) 2005-12-08
KR20020084115A (ko) 2002-11-04
CA2494241A1 (en) 2001-08-16
US20080213315A1 (en) 2008-09-04
NZ520201A (en) 2004-04-30
EP1398038B1 (en) 2007-01-10
PT1253932E (pt) 2005-07-29
PT1398038E (pt) 2007-02-28
TWI282739B (en) 2007-06-21
NZ530779A (en) 2004-08-27
TWI317283B (en) 2009-11-21
CA2400318C (en) 2005-06-14
CA2478621A1 (en) 2001-08-16

Similar Documents

Publication Publication Date Title
AR027391A1 (es) Composiciones farmaceuticas de toxina botulinica
HRP20020880B1 (en) New pharmaceutical composition
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
ZA200305412B (en) 4-fluoro-N-indan-2-yl benzamide and its use as pharmaceutical.
CR9351A (es) Composiciones y metodos para aplicaicon topica y suministro transdermico de toxina botulinica
CU23367A3 (es) Formulación de moxifloxacino con sal común
BRPI0515316A (pt) compostos de imidazoquinolina
BR0015605A (pt) Composição e uso
NZ593190A (en) Factor viii formulations
ES2195344T3 (es) Composicion farmaceutica que presenta una actividad antitumoral mejorada y/o efectos secundarios reducidos, que contiene un agente antitumoral y un derivado de acido hidroximico.
ATE364595T1 (de) Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
CO5160321A1 (es) Novedosas composiciones de tipranavir y ritonavir
BR0012696A (pt) Composição oftálmica
IL151628A0 (en) Combination therapies with vascular damaging activity
BR0111678A (pt) Composições medicinais contendo derivados de propenona
IT1314185B1 (it) Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi
ITMI20022292A1 (it) 9a-azalidi ad attivita' antiinfiammatoria.
NO20034504L (no) Erytropoietin forbedrer in vivo kjemoterapiindusert toksisitet
BRPI0611526A2 (pt) composição tópica contendo gelatina
BR0113165A (pt) Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
PA8449301A1 (es) Composiciones farmaceuticas
UY27373A1 (es) Formulaciones de interferón beta-humano
BRPI0410374A (pt) composição farmacêutica que compreende valsartano
AR037496A1 (es) Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables

Legal Events

Date Code Title Description
FC Refusal